<DOC>
	<DOCNO>NCT01170767</DOCNO>
	<brief_summary>Age Related Macular Degeneration ( AMD ) first cause visual impairment elderly patient industrialized country . Neovascular `` wet '' AMD , characterize presence choroïdal neovessels , represent aggressive form disease . Its prevalence 3.3 % among patient older 65 year Europe , increase age . Intraocular injection anti-angiogenic monoclonal antibody ( ranibizumab ) treat AMD appear recently . It derive large sized molecule , bevacizumab , market authorization indication . However , numerous publication case series seem show effectiveness satisfactory safety profile bevacizumab . These conclusion confirm high level evidence study . The aim GEFAL study demonstrate non-inferiority effectiveness clinical term 12 month treatment bevacizumab compare ranibizumab visual acuity patient affect neovascular AMD .</brief_summary>
	<brief_title>French Evaluation Group Avastin Versus Lucentis</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age ≥ 50 year old Affected neovascular retrofoveal AMD whatever subtype , unilateral bilateral ( eye include chosen investigator patient ) ; Best correct VA study eye range 20/32 ( 6.3/10 ) 20/320 ( 0.6/10 ) ETDRS scale Size lesion &lt; 12 disk area In case occult neovessels , proof require recent development lesion : loss VA least 5 letter ETDRS ( equivalent one line ) last 3 month OR appearance subretinal heamorrhage OR increase size lesion ( &gt; 10 % ) use fluoresceinic angiography last month comparison last 3 month OR appearance OCT criterion macular oedema type , serous separation neuroepithelium , separation pigment epithelial last month Effective birth control sexually active female Signed informed consent . Previous actual treatment intravitreal injection antiVEGF drug ( ranibizumab , bevacizumab pegaptanib ) study eye Other heal treatment study eye last 3 month first injection Medical history photocoagulation study eye Involvement another clinical study ( study eye and/or eye ) Subretinal haemorrhage reach fovea centre , size &gt; 50 % lesion area Fibrosis retrofoveal retinal atrophy study eye Retinal pigment epithelial tear reach macula study eye Choroidal neovascularisation relate DMLA study eye Medical history intravitreal medical device study eye Active suspect ocular periocular infection Serious active intraocular inflammation study eye Medical history autoimmune idiopathic uveitis Proved diabetic retinopathy Intraocular pressure ≥ 25 mmHg despite two topical hypotonic treatment Medical history intraocular surgery within 2 month first injection study eye Aphakia lack lens capsule ( remove YAG laser ) study eye Any illness ocular condition would require intraocular surgery study eye within 12 month inclusion Known hypersensitivity ranibizumab , bevacizumab , another drug composite medicinal product use ; allergy fluorescein , indocyanin green , anaesthetic eye drop Arterial hypertension control appropriate treatment Previous actual treatment systemic administration bevacizumab Follow possible 12 month No affiliation French national health insurance program .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Age-related Macular Degeneration</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>